EU Says India’s Alchem Is Part of International Drug Price-Fixing Cartel 6/14/2024

Proteins are workhorses that carry out most of the biological functions in our cells. While the genes we inherit from our parents, our so-called genome, are fixed and usually remain unchanged throughout our lives, proteins in our bodies are constantly changing, as we age, under different health conditions and upon stimulation, such as with medical treatment.

This makes monitoring proteins and their molecular changes - the study of proteomics - beneficial for drug discovery, disease diagnosis and health management.

Secondary Cancer Risk Is Low After CAR T Cell Treatment: Stanford Study 6/13/2024

Moderna’s Next-Gen COVID Vaccine Beats Current Shot in Pivotal Adult Efficacy Trial 6/13/2024

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Fails Phase III Trial 6/13/2024

Santa Ana Bio Launches With $168M, Targets Autoimmune and Inflammatory Diseases 6/13/2024

Foresite Raises $900M in Sixth Fund to Invest in Life Science Startups 6/13/2024

Massachusetts’ Life Sciences Job Growth Slows, but 10-Year Outlook Remains Strong: Report 6/13/2024

Coherus, Junshi’s PD-1 Blocker Loqtorzi Aces Phase III Liver Cancer Trial 6/13/2024

Career Coach: How to Navigate 2 Job Interviews at the Same Company 6/13/2024

Drugs with the potential to change the course of Alzheimer’s disease are expected to be approved by mid-year in the UK. Healthcare services may need to change to ensure that all patients have equitable access to these new modifying anti-amyloid therapies, according to research led by Queen Mary University of London and University College London (UCL).

Alzheimer's disease is the most common cause of dementia. Of the 944,000 people living with dementia in the UK, 60-80% have Alzheimer's.

A bacterial enzyme called histidine kinase is a promising target for new classes of antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is a "hydrophobic" protein that loses its structure once removed from its normal location in the cell membrane.

Now, an MIT-led team has found a way to make the enzyme water-soluble, which could make it possible to rapidly screen potential drugs that might interfere with its functions.

Researchers from Nagoya University Graduate School of Medicine in Japan have successfully treated the skin diseases epidermolytic ichthyosis (EI) and ichthyosis with confetti (IWC) by transplanting genetically healthy skin to inflamed areas. Transplanting healthy skin to inflamed areas has been used as a treatment option for severe burn injuries. They applied this technique from a common disease to rare diseases.

Diabetes rates continue to rise, with 11.7 million Canadians living with diabetes or pre-diabetes. At UBC, scientists have created a pain-free drug delivery method to help people with diabetes manage the disease and maintain their health more easily.

Researchers at the Li Lab have developed oral insulin drops that when placed under the tongue are quickly and efficiently absorbed by the body, potentially replacing the need for insulin injections.

GSK plc (LSE/NYSE: GSK) today announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million).

Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.

Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases 6/6/2024

Novo’s Ozempic, Wegovy to Face Stiff Generic Competition in China: Reuters 6/6/2024

Amgen Phase III Win Positions Uplizna for Label Expansion in Rare Autoimmune Disease 6/6/2024

BioSpace x DIA: Robust Integrated Regulatory Strategies 6/6/2024

Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report 6/6/2024